Translocator Protein Ligand Etifoxine Attenuates MPTP-Induced Neurotoxicity

Parkinson's disease (PD) is a neurodegenerative disease, but the currently available treatments for this disease are symptomatic treatments. There is evidence that translocator protein (18 kDa) (TSPO) expression is upregulated in some neurodegenerative diseases, and TSPO ligands have obvious ne...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in molecular neuroscience 2022-05, Vol.15, p.850904-850904
Main Authors: Tian, Qi, Yang, Xiaoxia, Du, Juan, Huang, Huachen, Liu, Wei, Zhao, Peng
Format: Article
Language:English
Subjects:
Alzheimer's disease
Animal cognition
Brain research
etifoxine
Experiments
Hydroxylase
Inflammation
Laboratory animals
Leukocytes
Ligands
Medical treatment
Microglia
Molecular Neuroscience
Movement disorders
MPTP
Neostriatum
Neurodegenerative diseases
neuroinflammation
Neuroprotection
Neurotoxicity
Parkinson's disease
Proteins
Substantia nigra
Traumatic brain injury
TSPO
Tyrosine 3-monooxygenase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson's disease (PD) is a neurodegenerative disease, but the currently available treatments for this disease are symptomatic treatments. There is evidence that translocator protein (18 kDa) (TSPO) expression is upregulated in some neurodegenerative diseases, and TSPO ligands have obvious neuroprotective effects. However, the neuroprotective effects and other potential effects of the TSPO ligand etifoxine in PD remain unclear. Therefore, the present study was designed to explore the impacts of etifoxine on a mouse model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We found that etifoxine significantly reduced motor function deficits, decreased the loss of tyrosine hydroxylase-positive neurons in the substantia nigra, and attenuated the decrease in striatal dopamine levels in mice that received MPTP. Etifoxine diminished the production of inflammatory mediators and infiltration of leukocytes in the brain after MPTP exposure. studies suggested that microglia contribute to etifoxine's neuroprotective effect. The results showed that etifoxine can alleviate MPTP-induced neurotoxicity and neuroinflammation, providing a new idea for the treatment of PD.
ISSN:1662-5099
1662-5099
DOI:10.3389/fnmol.2022.850904